Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 
News » Drug company receives FDA approval for high dose GERD treatment
 

Drug company receives FDA approval for high dose GERD treatment

The pharmaceutical company Santarus has received FDA approval for the first and only immediate-release oral proton pump inhibitor to be used by critically ill patients. It reduces the risk of upper gastrointestinal bleeding and provides short term treatment for active benign gastric ulcers. The product is called ZEGERID. The product allows for an immediate, higher dose product. Lower dose ZEGERID has already been approved for use as a short term treatment for active duodenal ulcers, heartburn, erosive esophagitis and other gastroesophageal reflux disease symptoms. The most common side effects associated with the drug include headache, diarrhea and abdominal pain. The medication should not be taken by people who are trying to restrict their sodium intake and by people who suffer from metabolic alkalosis and hypocalcemia.

Source: summary of medical news story as reported by Businesswire

Related Disease Topics:

Related Symptom Topics:

Article Source Details

About: Drug company receives FDA approval for high dose GERD treatment

Date: 22 December 2004

Source: Businesswire

URL: http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20041222005077&newsLang=en

Related Medical Topics

This summary article refers to the following medical categories:

More News Topics

  • Prisoners complain of inadequate health care
  • Problem of shortage of islet cell donors
  • Prolonged diagnosis causes loss of testicle for adolescent
  • Prolonged NSAIDs usage implicated in increased cancer risk
  • Prolonged use of HIV treatment leads to heart disease and stroke
  • Promiscuity linked to prostate cancer
  • Promised label warning on heart drug still not done after 1 year
  • Promising drugs raise dilemma of whether benefits outweigh the risks
  • Proposed over the counter cholesterol drug still under doubt
  • Prostate cancer active surveillance
  • Prostate cancer incidence increasing in Nigerian men
  • Prostate cancer often caused by lack of exposure to natural sunlight
  • Prostate cancer prognosis may be predicted by measuring levels of beta-catenin
  • Prostate cancer recurrence linked to obesity
  • Prostate cancer risk reduced in diabetics
  •  

    By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

    Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise